HealthDay - Abilify Approved as Additional Treatment for Major Depression
The U.S. Food and Drug Administration has approved Abilify (aripiprazole) as an add-on therapy for people with major depressive disorder who don’t benefit enough from antidepressant therapy alone, its makers said Tuesday.
Abilify, approved in November 2002 to treat schizophrenia, is among a class of medications called atypical antipsychotics. The latest approval followed clinical studies involving 743 patients.
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
Elderly people with dementia-related psychosis who are treated …
Read the full article with a Free Trial at MyWire.
